Global Healthcare Analyst

Tina Banerjee

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare companies. I have been helping investors to find future winners in healthcare space to grow their wealth by focusing on the strength and potential of the business models of the companies. My initiating coverage reports and pitch help investors to know ‘what to buy’, ‘why to buy’, and ‘when to buy’. My clients always remain on top of the sector with the help of my timely and detailed notes on earnings or any news update. I also provide broader view on the entire healthcare sector through periodic thematic reports.

Medipal Holdings (7459 JP): Mixed FY24 Result; Growth to Continue in FY25; Buyback Plan Announced

Medipal Holdings (7459 JP): Paltac (8283 JP) Acquisition to Release Margin Pressure

Medipal Holdings (7459 JP): Started FY24 On a Strong Note with Accelerated Revenue

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/medipal-holdings-corp" target="_blank" data-smartkarma-citation="entities:18394:1" rel="noopener">Medipal Holdings (7459 JP)</a> is facing pressure from the UK-based asset management firm, Silchester International to convene an EGM of shareholders. Silchester’s clients are Medipal’s largest shareholders.</li>
<li>Silchester formally demanded that Medipal convene an EGM to consider four proposals, including dismissal of Director Shuichi Watanabe, partial amendments to the Articles of Incorporation, special dividend, and share buyback.</li>
<li>Medipal has replaced Shuichi Watanabe and promoted Kuniaki Imagawa as the President and CEO ‘to enhance corporate value and achieve sustainable growth for Medipal under the new management structure.’ </li>
</ul>



Medipal Holdings (7459 JP) is facing pressure from the UK-based asset management firm, Silchester International to convene an EGM of shareholders. Silchester’s clients are Medipal’s largest shareholders.
Silchester formally demanded that Medipal convene an EGM to consider four proposals, including dismissal of Director Shuichi Watanabe, partial amendments to the Articles of Incorporation, special dividend, and share buyback.
Medipal has replaced Shuichi Watanabe and promoted Kuniaki Imagawa as the President and CEO ‘to enhance corporate value and achieve sustainable growth for Medipal under the new management structure.’ 


Medipal Holdings (7459 JP): Largest Investor’s Pressure Aims to Enhance Shareholder Value